CJC-1295

Description

This research-grade preparation contains CJC-1295, a 29-residue peptide modelled on the active fragment of growth hormone–releasing hormone (GHRH 1–29). The molecule incorporates a small number of amino acid substitutions that improve its biochemical stability in laboratory conditions, making it suitable for repeat-use protocols in cellular and ex-vivo work.

The mechanism of interest involves selective binding to the GHRH receptor (GHRHR) on pituitary somatotrophs. In experimental settings, this binding event has been studied for its role in initiating intracellular cAMP signalling, calcium mobilisation, and downstream gene-expression changes connected to the growth hormone axis. Pairing CJC-1295 with growth-hormone secretagogue peptides is a common protocol in comparative pharmacology work.

Typical research uses:

• Investigation of GHRHR binding affinity and downstream cAMP response
• Structure-activity studies comparing native GHRH (1–29) against modified analogues
• Combination assays with ghrelin-receptor agonists for synergy modelling
• In-vitro pituitary culture experiments measuring growth hormone release kinetics

Supplied as a sterile lyophilised peptide for in-vitro research only. Not for human or animal consumption. Purchasers must be 18 or older.